Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...

Looking at him now, our blue-eyed, funny, fearless little boy, Tom, it was all worth it. Every what if, every tear shed, ...

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a ...

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 20, 2025, Evaxion A/S announced positive data from its cytomegalovirus (CMV) ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing. NanoViricides’ Current ...

HemeNext 2025, held at The Westin Hotel, Gurgaon on the 22nd and 23rd of November, welcomed nearly 300 delegates from across the country, making it one of India's most anticipated gatherings in the ...

The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or ...

Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of ...

By integrating HIV care with non-communicable disease prevention and care, healthcare systems can help people living with HIV ...

The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment - an advance ...